On 24 January 2013, orphan designation (EU/3/12/1096) was granted by the European Commission to Serodapharm GmbH, Germany, for terguride for the treatment of systemic sclerosis.
The sponsorship was transferred to medac Gesellschaft für klinische Spezialpräparate mbH, Germany, in August 2016.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in March 2021 on request of the Sponsor.
Treatment of systemic sclerosis
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.